The Tax Cuts and Jobs Act of 2017 and the Pharmaceutical Industry

U.S Department of the Treasury, Office of Tax Analysis, Tax Expenditures, available at <https://www.treasury.gov/resource-center/tax-policy/Documents/Tax-Expenditures-FY2017.pdf> (last visited August 3, 2018).

U.S. Government Accountability Office, Corporate Income Tax – Most Large Profitable U.S. Corporations Paid Tax but Effective Tax Rates Differed Significantly from the Statutory Rate, GAO-16-363 (2016), available at <http://www.gao.gov/assets/680/675844.pdf> (last visited August 3, 2018).

Credit Suisse, US Biopharma Tax Analysis (2017), available at <https://research-doc.credit-suisse.com/docView?language=ENG&format=pdf&sourceid=emblast&document_id=1080024001&serialid=aHqk5tJr2lAqsjeCCoFdVsmFFXD4pp3dDsh6RmQTYOg%3D> (last visited September 19, 2018); Institute on Taxation and Economic Policy, Fortune 500 Companies Hold a Record $2.6 Trillion Offshore (2017), available at <https://itep.org/wp-content/uploads/pre0327.pdf> (last visited September 18, 2018).

Id.

U.S. Senate Permanent Subcommittee on Investigations, Repatriating Offshore Funds: 2004 Tax Windfall for Select Multinationals (2011) <https://www.hsgac.senate.gov/download/report-psi-majority-staff-report-repatriating-offshore-funds-oct-2011> (last visited August 3, 2018).

Id.

Office of Senator Cory A. Booker, With New Tax Savings, Drug Companies Start by Rewarding Shareholders, Not Patients Struggling with Skyrocketing Prices, April 19, 2018, available at <https://www.scribd.com/document/375935848/Pharma-Tax-Report-April-2018> (last visited August 3, 2018).

A.S. Kesselheim , Y.T. Tan , and J. Avorn , “The Roles of Academia, Rare Diseases, and Repurposing in the Development of the Most Transformative Drugs,” Health Affairs 34, no. 2 (2015):286-294.